<p>ANI 制药公司（NASDAQ:ANIP - 获取免费报告）的股票在目前覆盖该公司的九家评级机构中获得了平均 “买入” 评级，Marketbeat.com 报道。一位投资分析师给予该股票 “持有” 评级，七位分析师给予 “买入” 评级，还有一位分析师给予 “强力买入” 评级。在过去一年中，更新了对该股票覆盖的券商的平均十二个月目标价为 102.1429 美元。</p>
<p>获取 <strong>ANI 制药</strong> 的提醒：</p>
<p>几位股票分析师对该公司发表了看法。Guggenheim 将 ANI 制药的目标价从 114.00 美元上调至 115.00 美元，并在 11 月 10 日的研究报告中给予该公司 “买入” 评级。HC Wainwright 在 9 月 17 日的报告中将 ANI 制药的目标价从 93.00 美元上调至 121.00 美元，并给予 “买入” 评级。巴克莱在周二的报告中开始覆盖 ANI 制药的股票，给予 “增持” 评级和 100.00 美元的目标价。华尔街禅在 8 月 16 日的研究报告中将 ANI 制药的股票评级从 “买入” 上调至 “强力买入”。最后，Zacks Research 在 8 月 21 日的研究报告中将 ANI 制药的股票评级从 “持有” 上调至 “强力买入”。</p>
<p><strong>查看我们最新的 ANIP 股票报告</strong></p>
<h2>ANI 制药的内部买卖</h2>
<p>在 ANI 制药的其他新闻中，副总裁 Meredith Cook 在 11 月 13 日的交易中出售了 400 股公司的股票。该股票以 87.27 美元的平均价格出售，总价值为 34,908.00 美元。交易后，副总裁持有 75,274 股公司的股票，价值约为 6,569,161.98 美元。此次交易使其持股减少了 0.53%。该交易已在提交给证券交易委员会的文件中披露，您可以通过此链接访问。此外，董事 Renee P. Tannenbaum 在 12 月 5 日的交易中出售了 1,800 股公司的股票。该股票以 81.15 美元的平均价格出售，总价值为 146,070.00 美元。出售后，该董事直接持有 25,157 股公司的股票，价值约为 2,041,490.55 美元。这代表其持股减少了 6.68%。有关此次出售的更多细节可在官方 SEC 披露中找到。在过去的九十天里，内部人士共出售了价值 2,378,393 美元的 26,979 股公司股票。公司内部人士持有 11.10% 的股票。</p>
<h2>ANI 制药的机构交易</h2>
<p>对该股票的对冲基金最近增加或减少了其持股。查尔斯·施瓦布投资管理公司在第一季度将其在 ANI 制药的持股增加了 0.9%。查尔斯·施瓦布投资管理公司现在拥有 238,377 股这家专业制药公司的股票，价值 15,959,000 美元，此前在上个季度购买了 2,220 股。加拿大国家银行 FI 在第一季度购买了 ANI 制药的新头寸，价值 79,000 美元。Connor Clark &amp; Lunn 投资管理有限公司在第一季度将其在 ANI 制药的持股增加了 202.7%。Connor Clark &amp; Lunn 投资管理有限公司现在拥有 46,750 股这家专业制药公司的股票，价值 3,130,000 美元，此前在上个季度购买了 31,308 股。景顺有限公司在第一季度将其在 ANI 制药的持股增加了 1.0%。景顺有限公司现在拥有 199,567 股这家专业制药公司的股票，价值 13,361,000 美元，此前在上个季度购买了 2,022 股。最后，Nuveen LLC 在第一季度购买了 ANI 制药的新股份，价值 3,254,000 美元。机构投资者持有公司 76.05% 的股票。</p>
<h2>ANI 制药股票上涨 0.1%</h2>
<p>NASDAQ:ANIP 周五开盘价为 82.13 美元。该公司的债务与股本比率为 1.20，流动比率为 2.58，速动比率为 2.04。ANI 制药的股价在过去一年最低为 52.50 美元，最高为 99.50 美元。该公司的市值为 18.5 亿美元，市盈率为 50.39，贝塔值为 0.48。该公司的 50 日移动平均线为 87.79 美元，200 日移动平均线为 80.39 美元。</p>
<p>ANI 制药（NASDAQ:ANIP - 获取免费报告）最近于 11 月 7 日公布了季度财报。这家专业制药公司报告的每股收益为 2.04 美元，超出市场共识预期的 1.74 美元，超出幅度为 0.30 美元。该公司本季度的收入为 2.2781 亿美元，而分析师预期为 2.1192 亿美元。ANI 制药的净利润率为 4.91%，股本回报率为 26.73%。该公司本季度的收入较去年同期增长了 53.6%。去年同期，该公司每股收益为 1.34 美元。ANI 制药已将其 2025 财年的指导目标设定为每股收益 7.370-7.640 美元。作为一个整体，股票研究分析师预计 ANI 制药在当前财年将发布每股收益 3.86 美元。</p>
<h2>ANI 制药公司简介</h2>
<p>（获取免费报告）</p>
<p>ANI 制药公司是一家生物制药公司，在美国和加拿大开发、生产和销售品牌和仿制处方药。该公司生产口服固体剂型；半固体、液体和外用剂型；受控物质；以及强效产品，并进行药品的合同开发和生产。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票，而不是 ANI Pharmaceuticals</li>
<li>什么是便士股票？全面指南</li>
<li>2026 年需避免的三只最近被下调评级的股票</li>
<li>罗素 2000 指数，投资者如何利用它进行盈利交易</li>
<li>芯片热潮回归：三只有望大幅上涨的股票</li>
<li>多元化可以平滑收益并降低投资组合风险</li>
<li>甲骨文股票遭重创：其人工智能管道为何可能推动 2026 年反弹</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU5JUA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU5JUA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 $1,000 在 ANI Pharmaceuticals 吗？</h2>
<p>在考虑 ANI Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 ANI Pharmaceuticals 并不在名单上。</p>
<p>虽然 ANI Pharmaceuticals 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

ANI制药

<p>ANI 制药公司（NASDAQ:ANIP）获得了九位分析师的一致 “买入” 评级，目标价格为 102.14 美元。内部交易方面，副总裁梅雷迪斯·库克和董事雷妮·P·坦嫩鲍姆出售了股份，而查尔斯·施瓦布和康纳·克拉克与伦恩等机构投资者则增加了持股。该股票开盘价为 82.13 美元，市值为 18.5 亿美元，市盈率为 50.39。最近的财报显示每股收益为 2.04 美元，营收为 2.2781 亿美元，超出预期</p>

<p>Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) have earned an average rating of &#34;Buy&#34; from the nine ratings firms that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $102.1429.</p>
<div class="lb-trans"><p>ANI 制药公司（NASDAQ:ANIP - 获取免费报告）的股票在目前覆盖该公司的九家评级机构中获得了平均 “买入” 评级，Marketbeat.com 报道。一位投资分析师给予该股票 “持有” 评级，七位分析师给予 “买入” 评级，还有一位分析师给予 “强力买入” 评级。在过去一年中，更新了对该股票覆盖的券商的平均十二个月目标价为 102.1429 美元。</p>
</div><p>Get <strong>ANI Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>ANI 制药</strong> 的提醒：</p>
</div><p>Several equities analysts have weighed in on the company. Guggenheim raised their price objective on ANI Pharmaceuticals from $114.00 to $115.00 and gave the company a &#34;buy&#34; rating in a research note on Monday, November 10th. HC Wainwright increased their target price on shares of ANI Pharmaceuticals from $93.00 to $121.00 and gave the company a &#34;buy&#34; rating in a report on Wednesday, September 17th. Barclays initiated coverage on shares of ANI Pharmaceuticals in a report on Tuesday. They set an &#34;overweight&#34; rating and a $100.00 price target on the stock. Wall Street Zen raised shares of ANI Pharmaceuticals from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research report on Saturday, August 16th. Finally, Zacks Research raised shares of ANI Pharmaceuticals from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research report on Thursday, August 21st.</p>
<div class="lb-trans"><p>几位股票分析师对该公司发表了看法。Guggenheim 将 ANI 制药的目标价从 114.00 美元上调至 115.00 美元，并在 11 月 10 日的研究报告中给予该公司 “买入” 评级。HC Wainwright 在 9 月 17 日的报告中将 ANI 制药的目标价从 93.00 美元上调至 121.00 美元，并给予 “买入” 评级。巴克莱在周二的报告中开始覆盖 ANI 制药的股票，给予 “增持” 评级和 100.00 美元的目标价。华尔街禅在 8 月 16 日的研究报告中将 ANI 制药的股票评级从 “买入” 上调至 “强力买入”。最后，Zacks Research 在 8 月 21 日的研究报告中将 ANI 制药的股票评级从 “持有” 上调至 “强力买入”。</p>
</div><p><strong>Check Out Our Latest Stock Report on ANIP</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 ANIP 股票报告</strong></p>
</div><h2>Insider Buying and Selling at ANI Pharmaceuticals</h2>
<div class="lb-trans"><h2>ANI 制药的内部买卖</h2>
</div><p>In other ANI Pharmaceuticals news, VP Meredith Cook sold 400 shares of the business's stock in a transaction on Thursday, November 13th. The stock was sold at an average price of $87.27, for a total value of $34,908.00. Following the transaction, the vice president owned 75,274 shares of the company's stock, valued at approximately $6,569,161.98. The trade was a 0.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through this link. Also, Director Renee P. Tannenbaum sold 1,800 shares of the firm's stock in a transaction on Friday, December 5th. The shares were sold at an average price of $81.15, for a total value of $146,070.00. Following the sale, the director directly owned 25,157 shares of the company's stock, valued at approximately $2,041,490.55. This represents a 6.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 26,979 shares of company stock valued at $2,378,393 in the last ninety days. 11.10% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在 ANI 制药的其他新闻中，副总裁 Meredith Cook 在 11 月 13 日的交易中出售了 400 股公司的股票。该股票以 87.27 美元的平均价格出售，总价值为 34,908.00 美元。交易后，副总裁持有 75,274 股公司的股票，价值约为 6,569,161.98 美元。此次交易使其持股减少了 0.53%。该交易已在提交给证券交易委员会的文件中披露，您可以通过此链接访问。此外，董事 Renee P. Tannenbaum 在 12 月 5 日的交易中出售了 1,800 股公司的股票。该股票以 81.15 美元的平均价格出售，总价值为 146,070.00 美元。出售后，该董事直接持有 25,157 股公司的股票，价值约为 2,041,490.55 美元。这代表其持股减少了 6.68%。有关此次出售的更多细节可在官方 SEC 披露中找到。在过去的九十天里，内部人士共出售了价值 2,378,393 美元的 26,979 股公司股票。公司内部人士持有 11.10% 的股票。</p>
</div><h2>Institutional Trading of ANI Pharmaceuticals</h2>
<div class="lb-trans"><h2>ANI 制药的机构交易</h2>
</div><p>Hedge funds have recently added to or reduced their stakes in the stock. Charles Schwab Investment Management Inc. increased its stake in shares of ANI Pharmaceuticals by 0.9% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 238,377 shares of the specialty pharmaceutical company's stock worth $15,959,000 after purchasing an additional 2,220 shares during the last quarter. National Bank of Canada FI bought a new position in ANI Pharmaceuticals during the first quarter valued at $79,000. Connor Clark &amp; Lunn Investment Management Ltd. increased its position in ANI Pharmaceuticals by 202.7% in the first quarter. Connor Clark &amp; Lunn Investment Management Ltd. now owns 46,750 shares of the specialty pharmaceutical company's stock worth $3,130,000 after buying an additional 31,308 shares during the last quarter. Invesco Ltd. increased its position in ANI Pharmaceuticals by 1.0% in the first quarter. Invesco Ltd. now owns 199,567 shares of the specialty pharmaceutical company's stock worth $13,361,000 after buying an additional 2,022 shares during the last quarter. Finally, Nuveen LLC bought a new stake in shares of ANI Pharmaceuticals in the first quarter valued at $3,254,000. Institutional investors own 76.05% of the company's stock.</p>
<div class="lb-trans"><p>对该股票的对冲基金最近增加或减少了其持股。查尔斯·施瓦布投资管理公司在第一季度将其在 ANI 制药的持股增加了 0.9%。查尔斯·施瓦布投资管理公司现在拥有 238,377 股这家专业制药公司的股票，价值 15,959,000 美元，此前在上个季度购买了 2,220 股。加拿大国家银行 FI 在第一季度购买了 ANI 制药的新头寸，价值 79,000 美元。Connor Clark &amp; Lunn 投资管理有限公司在第一季度将其在 ANI 制药的持股增加了 202.7%。Connor Clark &amp; Lunn 投资管理有限公司现在拥有 46,750 股这家专业制药公司的股票，价值 3,130,000 美元，此前在上个季度购买了 31,308 股。景顺有限公司在第一季度将其在 ANI 制药的持股增加了 1.0%。景顺有限公司现在拥有 199,567 股这家专业制药公司的股票，价值 13,361,000 美元，此前在上个季度购买了 2,022 股。最后，Nuveen LLC 在第一季度购买了 ANI 制药的新股份，价值 3,254,000 美元。机构投资者持有公司 76.05% 的股票。</p>
</div><h2>ANI Pharmaceuticals Trading Up 0.1%</h2>
<div class="lb-trans"><h2>ANI 制药股票上涨 0.1%</h2>
</div><p>NASDAQ:ANIP opened at $82.13 on Friday. The company has a debt-to-equity ratio of 1.20, a current ratio of 2.58 and a quick ratio of 2.04. ANI Pharmaceuticals has a one year low of $52.50 and a one year high of $99.50. The company has a market cap of $1.85 billion, a PE ratio of 50.39 and a beta of 0.48. The firm has a 50-day moving average of $87.79 and a 200-day moving average of $80.39.</p>
<div class="lb-trans"><p>NASDAQ:ANIP 周五开盘价为 82.13 美元。该公司的债务与股本比率为 1.20，流动比率为 2.58，速动比率为 2.04。ANI 制药的股价在过去一年最低为 52.50 美元，最高为 99.50 美元。该公司的市值为 18.5 亿美元，市盈率为 50.39，贝塔值为 0.48。该公司的 50 日移动平均线为 87.79 美元，200 日移动平均线为 80.39 美元。</p>
</div><p>ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last announced its quarterly earnings results on Friday, November 7th. The specialty pharmaceutical company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.74 by $0.30. The business had revenue of $227.81 million for the quarter, compared to analysts' expectations of $211.92 million. ANI Pharmaceuticals had a net margin of 4.91% and a return on equity of 26.73%. The firm's revenue for the quarter was up 53.6% compared to the same quarter last year. During the same quarter last year, the firm earned $1.34 EPS. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. As a group, equities research analysts expect that ANI Pharmaceuticals will post 3.86 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>ANI 制药（NASDAQ:ANIP - 获取免费报告）最近于 11 月 7 日公布了季度财报。这家专业制药公司报告的每股收益为 2.04 美元，超出市场共识预期的 1.74 美元，超出幅度为 0.30 美元。该公司本季度的收入为 2.2781 亿美元，而分析师预期为 2.1192 亿美元。ANI 制药的净利润率为 4.91%，股本回报率为 26.73%。该公司本季度的收入较去年同期增长了 53.6%。去年同期，该公司每股收益为 1.34 美元。ANI 制药已将其 2025 财年的指导目标设定为每股收益 7.370-7.640 美元。作为一个整体，股票研究分析师预计 ANI 制药在当前财年将发布每股收益 3.86 美元。</p>
</div><h2>ANI Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>ANI 制药公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.</p>
<div class="lb-trans"><p>ANI 制药公司是一家生物制药公司，在美国和加拿大开发、生产和销售品牌和仿制处方药。该公司生产口服固体剂型；半固体、液体和外用剂型；受控物质；以及强效产品，并进行药品的合同开发和生产。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than ANI Pharmaceuticals</li>
<li>What is a penny stock? A comprehensive guide</li>
<li>3 Recently Downgraded Stocks to Avoid in 2026</li>
<li>Russell 2000 Index, How Investors Use it For Profitable Trading</li>
<li>The Chip Boom Is Back: 3 Stocks Positioned for Huge Gains</li>
<li>Diversification Can Smooth Returns And Mitigate Portfolio Risk</li>
<li>Oracle Stock Hit Hard: Why Its AI Pipeline Could Drive a 2026 Rally</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 ANI Pharmaceuticals</li>
<li>什么是便士股票？全面指南</li>
<li>2026 年需避免的三只最近被下调评级的股票</li>
<li>罗素 2000 指数，投资者如何利用它进行盈利交易</li>
<li>芯片热潮回归：三只有望大幅上涨的股票</li>
<li>多元化可以平滑收益并降低投资组合风险</li>
<li>甲骨文股票遭重创：其人工智能管道为何可能推动 2026 年反弹</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU5JUA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=ANIP"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in ANI Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 ANI Pharmaceuticals 吗？</h2>
</div><p>Before you consider ANI Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 ANI Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ANI Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 ANI Pharmaceuticals 并不在名单上。</p>
</div><p>While ANI Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 ANI Pharmaceuticals 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

ANI 制药公司（NASDAQ:ANIP）被分析师一致评级为 “买入”